Global Microbiome Research Report 2023: Market Booming with Breakthrough Treatments for Recurrent C. Difficile Infection, Fecal Microbial Transplantation (FMT) Emerges as a Game-Changer - ResearchAndMarkets.com

The microbiome therapeutics market is successfully commercializing Seres Therapeutics' SER-109 and Rebiotix's RBX-2660 for recurrent Clostridium difficile infection (Recurrent C. difficile).